Development of Leprosy and Type 1 Leprosy Reactions after Treatment with Infliximab: A Report of 2 Cases
Authors:
Open Access
- 15 July 2006
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (2) , e19-e22
Abstract
Humanized monoclonal antibodies to tumor necrosis factor–α are valuable for the treatment of rheumatologic conditions, but they have been associatedKeywords
This publication has 12 references indexed in Scilit:
- The Continuing Challenges of LeprosyClinical Microbiology Reviews, 2006
- Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximabSeminars in Arthritis and Rheumatism, 2005
- Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisoneCanadian Medical Association Journal, 2004
- Infliximab treatment of rheumatoid arthritisRheumatic Disease Clinics of North America, 2004
- Leishmaniasis visceral con relación a la administración de infliximabEnfermedades Infecciosas y Microbiología Clínica, 2004
- Borderline Tuberculoid Leprosy: An Immune Reconstitution Phenomenon in a Human Immunodeficiency Virus–Infected PersonClinical Infectious Diseases, 2003
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Exacerbation of Acute and Chronic Murine Tuberculosis by Administration of a Tumor Necrosis Factor Receptor-Expressing AdenovirusThe Journal of Infectious Diseases, 1995
- The Development and Adaptation of the Semmes-Weinstein Monofilaments in BrazilJournal of Hand Therapy, 1993
- The Use of a Specific DNA Probe and Polymerase Chain Reaction for the Detection of Mycobacterium lepraeThe Journal of Infectious Diseases, 1990